Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

BACKGROUND: The purpose of this study was to investigate the potential of antibody-directed immunotherapy targeting the aminophospholipid phosphatidylserine, which promotes immunosuppression when exposed in the tumor microenvironment, alone and in combination with antibody treatment towards the T-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Michael J., Gong, Jian, Hatch, Michaela M. S., Nguyen, Van, Hughes, Christopher C. W., Hutchins, Jeff T., Freimark, Bruce D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864933/
https://www.ncbi.nlm.nih.gov/pubmed/27169467
http://dx.doi.org/10.1186/s13058-016-0708-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864933/
https://www.ncbi.nlm.nih.gov/pubmed/27169467
http://dx.doi.org/10.1186/s13058-016-0708-2

Ejemplares similares